Advertisement

Surgery Today

, 41:801 | Cite as

Trends in the treatment outcomes for advanced colorectal cancer: An analysis at a single community hospital in Japan

  • Morimasa Tomikawa
  • Daisuke Korenaga
  • Tomohiko Akahoshi
  • Kenichi Kohshi
  • Keishi Sugimachi
  • Yasuharu Ikeda
  • Kenji Takenaka
  • Yoshihiko Maehara
Original Article

Abstract

Purpose

To evaluate the trends in the treatment outcomes for patients with colorectal cancer in Japan.

Methods

We performed a retrospective analysis of patients undergoing surgery for primary colorectal cancer during a 16-year period (Group A [1992–2000, n = 258]; Group B [2001–2008, n = 258]) at Fukuoka City Hospital. Because no significant differences were found in the survival rates in stage 0, I, II, and III patients between the two groups, we concentrated on examining stage IV patients.

Results

The 3-year survival rate for stage IV patients in Group B (n = 26) was significantly higher than that in Group A (n = 31) (34.9% vs 3.9%, P < 0.05). The rate of curative resection for advanced liver metastases in Group B patients was also significantly higher than that of Group A patients (50.0% vs 13.3%, P < 0.05). As a result, the 2-year survival rate for the disease-free patients in Group B was significantly higher than that for the non-disease-free patients in Group B (46.0% vs 21.0%, P < 0.05). Group B had a greater proportion of patients receiving l-leucovorin/5-fluorouracil than Group A (8 patients vs none, P < 0.05).

Conclusions

Recent advances in surgical innovations and the utilization of new chemotherapeutic agents may have led to significant improvements in the treatment outcomes for advanced colorectal cancer in Japan.

Key words

Colorectal cancer Liver resection Disease-free status Chemotherapy 

References

  1. 1.
    The Editorial Board of the Cancer Statistics in Japan (editor). Cancer statistics in Japan 2007. Foundation for Promotion of Cancer Research (FPCR), Japan; 2007.Google Scholar
  2. 2.
    Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, et al. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and l-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. Jpn J Clin Oncol 2007;37:686–691.PubMedCrossRefGoogle Scholar
  3. 3.
    Espey DK, Wu XC, Swan J, Wiggins C, Jim MA, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer 2007;110:2119–2152.PubMedCrossRefGoogle Scholar
  4. 4.
    U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2004 incidence and mortality. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2007.Google Scholar
  5. 5.
    Jackson-Thompson J, Ahmed F, German R, Lai S, Friedman C. Descriptive epidemiology of colorectal cancer in the United States, 1998–2001. Cancer 2006;107(5 suppl):1103–1111.PubMedCrossRefGoogle Scholar
  6. 6.
    Konishi T, Watanabe T, Kishimoto J, Nagawa H. Elective colon and rectal surgery differ in risk factors for wound infection: results of prospective surveillance. Ann Surg 2006;244:758–763.PubMedCrossRefGoogle Scholar
  7. 7.
    Nakamura T, Onozato W, Mitomi H, Naito M, Sato T, Ozawa H, et al. Retrospective, matched case-control study comparing the oncologic outcomes between laparoscopic surgery and open surgery in patients with right-sided colon cancer. Surg Today 2009;39:1040–1045.PubMedCrossRefGoogle Scholar
  8. 8.
    Yasunaga H, Matsuyama Y, Ohe K; Japan Surgical Society. Volume-outcome relationship in rectal cancer surgery: a new perspective. Surg Today 2009;39:663–668.PubMedCrossRefGoogle Scholar
  9. 9.
    Yasunaga H, Matsuyama Y, Ohe K; Japan Surgical Society. Effects of hospital and surgeon volumes on operating times, postoperative complications, and length of stay following laparoscopic colectomy. Surg Today 2009;39:955–961.PubMedCrossRefGoogle Scholar
  10. 10.
    Hida J, Okuno K, Yasutomi M, Yoshifuji T, Matsuzaki T, Uchida T, et al. Number versus distribution in classifying regional lymph node metastases from colon cancer. J Am Coll Surg 2005; 201:217–222.PubMedCrossRefGoogle Scholar
  11. 11.
    Rosen SA, Buell JF, Yoshida A, Kazsuba S, Hurst R, Michelassi F, et al. Initial presentation with Stage IV colorectal cancer: how aggressive should we be? Arch Surg 2000;135:530–535.PubMedCrossRefGoogle Scholar
  12. 12.
    Adam R. The importance of visceral metastasectomy in colorectal cancer. Ann Oncol 2000;11(suppl 3):29–36.PubMedCrossRefGoogle Scholar
  13. 13.
    Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759–766.PubMedCrossRefGoogle Scholar
  14. 14.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 1999;230:309–321.PubMedCrossRefGoogle Scholar
  15. 15.
    de Santibañes E, Lassalle FB, McCormack L, Pekolj J, Quintana GO, Vaccaro C, et al. Simultaneous colorectal and hepatic resection for colorectal cancer: postoperative and long-term outcomes. J Am Coll Surg 2002;195:196–202.PubMedCrossRefGoogle Scholar
  16. 16.
    Toshiniko S, Noriaki T, Koichiro I, Tsuyoshi Y, Hidehito M, Masahiro Y. Pulmonary resection for metastases from colorectal cancer. Chest 2001;119:1069–1072.CrossRefGoogle Scholar
  17. 17.
    Rizk NP, Downey RJ. Resection of pulmonary metastases from colorectal cancer. Semin Thorac Cardiovasc Surg 2002;14:29–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Headrick JR, Miller DL, Nagorney DM, Allen MS, Deschamps C, Trastek VF, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg 2001;71:975–979.PubMedCrossRefGoogle Scholar
  19. 19.
    Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, et al. Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 2002;25:65–70.PubMedCrossRefGoogle Scholar
  20. 20.
    Díaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortés-Funes H, de Braud F, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 1998;9:105–108.PubMedCrossRefGoogle Scholar
  21. 21.
    Bécouarn Y, Gamelin E, Coudert B, Négrier S, Pierga JY, Raoul JL, et al. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patient. J Clin Oncol 2001;19:4195–4201.PubMedGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Morimasa Tomikawa
    • 1
    • 2
  • Daisuke Korenaga
    • 1
  • Tomohiko Akahoshi
    • 1
    • 2
  • Kenichi Kohshi
    • 1
  • Keishi Sugimachi
    • 2
  • Yasuharu Ikeda
    • 1
  • Kenji Takenaka
    • 1
  • Yoshihiko Maehara
    • 2
  1. 1.Department of SurgeryFukuoka City HospitalFukuokaJapan
  2. 2.Department of Surgery and Science, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations